2019 is an important transformation and key upgrade year for the development of my country's pharmaceutical industry. The pace of industrial reform has accelerated, the pace of market opening has accelerated, and the growth of the industry has slowed down, but the quality of industrial operations has improved. Driven by new environmental pressures such as encouraging competition, centralized procurement, price reduction, rational use of medicines, medical insurance control fees, trade frictions, etc., innovation, green, sharing, high-quality, internationalization, smart manufacturing, Internet++ and other new dynamics are advancing the pharmaceutical industry Rapid transformation and upgrading. As an important part of the seven major areas of strategic emerging industries, the biomedical industry has accelerated the supply-side structural reform, rationally subtracted, and efficiently added, maintaining a relatively stable momentum and continuing to increase its contribution to economic development.
The growth rate of the added value of the pharmaceutical industry is ups and downs
According to the "Report on the Economic Operation of China's Pharmaceutical Industry in 2019" issued by the China Pharmaceutical Enterprise Management Association in October 2020, it was pointed out that the growth rate of China's pharmaceutical industry from 2015 to 2020 showed a fluctuating downward trend. In 2015, the growth rate of the added value of China's pharmaceutical industry rose from 9.8% to 12.4% in 2017 and then fell to 4.6% in November 2020. Compared with the growth rate of the national industrial added value above designated size, the growth rate of my country's pharmaceutical industry has experienced more ups and downs.
The economic performance of China's pharmaceutical industry is performing well
According to data from the China Pharmaceutical Enterprise Management Association, due to statistical problems, the economic benefits of China's pharmaceutical industry have shown a downward trend year by year. The growth rate has remained positive but the growth rate has slowed year by year. In 2019, the operating income of China's pharmaceutical industry was 2.61 trillion yuan, a year-on-year increase of 8%; while profits were 345.7 billion yuan, a year-on-year increase of 7%. Prospects Based on the development of China's pharmaceutical industry in recent years, it is predicted that the operating income of China's pharmaceutical industry in 2020 will be approximately 2.37 trillion yuan and the profit will be approximately 339.2 billion yuan.
From the perspective of the export delivery value of China's pharmaceutical industry, the export delivery value of China's pharmaceutical industry has fluctuated due to statistical problems. The growth rate has remained positive but the growth rate has slowed down year by year. In 2019, the export delivery value of China's pharmaceutical industry was 211.7 billion yuan, a year-on-year increase of 7%. Forward-looking forecasts that in 2020, the export delivery value of China's pharmaceutical industry will be approximately 220.9 billion yuan.
Chemical preparations manufacturing became the leader of the sub-industry
According to data from the China Pharmaceutical Enterprise Management Association, the operating revenue of chemical pharmaceutical preparations manufacturing in 2019 was 857.61 billion yuan, an increase of 11.5% year-on-year, accounting for 32.8% of the pharmaceutical industry's revenue that year. The second is the production of Chinese patent medicines, which achieved revenue of 458.7 billion yuan, an increase of 7.5% year-on-year, accounting for 17.5% of the pharmaceutical industry's revenue that year.
The other is the manufacturing of chemical raw materials. In 2019, it achieved operating income of 380.37 billion yuan, a year-on-year increase of 5%, accounting for 14.6% of the pharmaceutical industry's revenue that year.
The profitability of biopharmaceutical manufacturing far exceeds other sub-sectors
According to data from the China Pharmaceutical Enterprise Management Association, the profit of chemical preparations manufacturing in 2019 was 117.27 billion yuan, an increase of 14.6% year-on-year, accounting for 33.9%, and the profit margin was 13.7%. From the perspective of profitability, although the total profit of biopharmaceutical manufacturing is only 48.54 billion yuan, a year-on-year increase of 14%, the profit rate is the highest, reaching 19.6%; followed by the profit rate of medical equipment and equipment manufacturing reaching 14.4%.
